189 related articles for article (PubMed ID: 27658663)
41. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
42. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
Paffenholz P; Pfister D; Heidenreich A
Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
[TBL] [Abstract][Full Text] [Related]
43. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
[TBL] [Abstract][Full Text] [Related]
44. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer.
Pettus JA; Carver BS; Masterson T; Stasi J; Sheinfeld J
Urology; 2009 Feb; 73(2):328-31; discussion 331-2. PubMed ID: 19022490
[TBL] [Abstract][Full Text] [Related]
45. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
46. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection.
Donohue JP; Thornhill JA; Foster RS; Rowland RG; Bihrle R
Eur J Cancer; 1995 Sep; 31A(10):1599-604. PubMed ID: 7488408
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
48. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
49. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
[TBL] [Abstract][Full Text] [Related]
50. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer.
Mosharafa AA; Foster RS; Koch MO; Bihrle R; Donohue JP
J Urol; 2004 May; 171(5):1839-41. PubMed ID: 15076289
[TBL] [Abstract][Full Text] [Related]
51. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
Calaway AC; Kern SQ; Crook D; Tong Y; Masterson TA; Adra N; Einhorn LH; Foster RS; Cary C
J Urol; 2021 Dec; 206(6):1430-1437. PubMed ID: 34288715
[TBL] [Abstract][Full Text] [Related]
52. Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
Gupta A; Feifer AH; Gotto GT; Kraus D; Motzer R; Bosl GJ; Bajorin D; Feldman DR; Carver B; Sheinfeld J
Urology; 2011 Mar; 77(3):655-9. PubMed ID: 21377010
[TBL] [Abstract][Full Text] [Related]
53. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
54. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
55. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
[TBL] [Abstract][Full Text] [Related]
56. Quality of life after laparoscopic and open retroperitoneal lymph node dissection in clinical Stage I nonseminomatous germ cell tumor: a comparison study.
Poulakis V; Skriapas K; de Vries R; Dillenburg W; Ferakis N; Witzsch U; Becht E
Urology; 2006 Jul; 68(1):154-60. PubMed ID: 16820195
[TBL] [Abstract][Full Text] [Related]
57. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors.
Bhanvadia R; Ashbrook C; Bagrodia A; Lotan Y; Margulis V; Woldu S
World J Urol; 2021 Jun; 39(6):1977-1984. PubMed ID: 32797261
[TBL] [Abstract][Full Text] [Related]
58. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data.
Williams SB; McDermott DW; Winston D; Bahnson E; Berry AM; Steele GS; Richie JP
BJU Int; 2010 Apr; 105(7):918-21. PubMed ID: 19747353
[TBL] [Abstract][Full Text] [Related]
59. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors.
Carver BS; Sheinfeld J
Nat Clin Pract Urol; 2005 Jul; 2(7):330-5. PubMed ID: 16474785
[TBL] [Abstract][Full Text] [Related]
60. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection?
Jacobsen NE; Beck SD; Jacobson LE; Bihrle R; Einhorn LH; Foster RS
J Urol; 2010 Sep; 184(3):949-53. PubMed ID: 20643453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
